Coala named "Cool Vendor 2018" by Gartner


STOCKHOLM 2018-08-15. Coala Life announced today that it has been named “Cool Vendor 2018” by Gartner Inc, the world's leading research and advisory company. The announcement is made within the market of Health and Wellness Devices and Coala is joined by four other impressive US and UK-based companies.

- It is an honor to be named Gartner “Cool Vendor”, said Philip Siberg, co-founder and CEO of Coala Life. Gartner is the world's leading research and advisory company and their designation validates our mission and commitment to develop solutions that help win the battle against the leading cause of death. We join an exclusive club of companies, of which many Cool Vendors have scaled up to become global leaders.

The announcement is based on the August 13, 2018 report, titled “Cool Vendors in Health and Wellness Devices, 2018” by David Glenn et al. at Gartner Inc. The report evaluates interesting, new and innovative vendors, products and services in the health and wellness market. The Gartner Cool Vendor 2018 report summarizes that health and wellness devices provide valuable data for personal self-awareness and healthcare professionals. Technology product marketers in the health and wellness ecosystem should expand their device sales channels to target nonclinical healthcare-related providers. The complete report is available here,

Gartner's definition of a Cool Vendor is a small company offering a technology or service that is:

  • Innovative — enables users to do things they couldn't do before
  • Impactful — has or will have a business impact, not just technology for its own sake
  • Intriguing — has caught Gartner's interest during the past six months

For more info:
Philip Siberg, CEO and co-founder, +46 70 7906734,
Titti Lundgren, CMO, +46 70 8353328,

About Coala Life
Coala Life is a Swedish digital health venture focused on cardiac diagnostics and digital health. The company has developed a portfolio of patented medical products and services for user-centered digital remote monitoring and screening of the heart based on advanced and smart algorithms. Coala's solutions enable analysis, remote monitoring, more effective cardiac assessments and integrated care services, all in real time. Follow your Heart®. For more information see,

About Gartner
For more information see,

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Coala Life raises additional growth capital


STOCKHOLM JUNE 6th, 2018 – Coala Life has raised an additional 16 million SEK (approx. USD 2 million) in growth capital to further accelerate its commercialization. Investors include 20 North Street, Larry Leksell, international business angels and senior executives in the company. 

"We’ve now raised over SEK 110 million [approx. USD 12.5 million] on our mission to develop unique solutions for individual and patient-centered cardiac analysis. It’s about improving clinical accessibility, productivity and sensitivity, and to generate data that can be used to predict heart disease based on our AI-algorithms to help win the battle against the world's leading cause of death", commented Philip Siberg, CEO and co-founder of Coala Life.

The raised capital aims to accelerate commercialization within the consumer market and further drive the digitization of cardiac care.

As of today, the Coala-system has analyzed over 100,000 ECG’s with approximately 100 healthcare providers and 250 physicians connected to the platform. Many previously unknown cases of heart disease have been detected and treated, and the solutions have shown to improve healthcare productivity and alleviate worries with very strong clinical sensitivity and specificity.

Coala Life was founded and supported by a number of leading entrepreneurs, industry leaders and investors in the Life Science industry including Larry Leksell (chairman and founder of Elekta AB), Sören Olofsson (former CEO of some of Sweden’s largest hospitals and County Council CEO) and Liselott Kilaas (former President and CEO of Aleris, the largest health care provider in Scandinavia).

For more info:

Philip Siberg, CEO and co-founder, +46 70 7906734,

Titti Lundgren, Chief Marketing Officer, +46 708 3533 28,

Super-quartet joins the Coala team



Coala Life strengthens the organization further with new Chairman, Board member, Business Development Manager and Customer Experience Manager.

"We welcome a super-quartet to further accelerate our position as the leader in digital solutions and services for the heart," commented Philip Siberg, CEO of Coala Life.

Liselott Kilaas joins as new chairman of Coala Life. Liselott has a 30-year career including roles as the CEO of Aleris, the largest healthcare provider in Scandinavia, and as a member of the Board of Telenor ASA and the Norwegian Central Bank. Liselott is currently Board Member of Orkla ASA, Det Norske Veritas (DNV) and Peab AB, to name a few.

"I am very committed to health issues and I see great potential in Coala Life and how digital solutions can help to improve care," commented Liselott Kilaas, new chairman of Coala Life. 

Johanna Öberg joins as new Board member of Coala Life. Johanna is the CEO of Memira, Scandinavia's largest healthcare provider within eye lens and lens replacement surgeries. Johanna has a long career, including a turn-around of the leading media group Stampen as CEO, nas has worked within the Kinnevik group and launched the newspaper Metro in Puerto Rico.

Anna Hernegran joins as Business Development Manager. Anna brings in a successful career from Philips Healthcare where she was responsible for developing sales within Imaging and Cardiology markets. Annas focus at Coala is primarily to further develop our business and drive sales in the healthcare markets and work with our great partners.

Malin Sendén joins as Customer Experience Manager. Malin recently worked for Global Kinetics, a digital medical technology company. Malin will focus on delivering the best customer experience to the consumer, patient and healthcare.

The RedHeart Study

redheart intressanmälan eng.png


Introducing the RedHeart Study - the largest clinical study to date on solely the female heart using the digital tools to study palpitations and quality of life

The Red Heart Study is a scientific study in collaboration between Karolinska Institutet, 1.6Mlijonerklubben and Coala Life. The aim of the study is to identify, using smart ECG techniques, the type of heart rhythms that causes your symptoms, and to study the extent to which your palpitation causes discomfort in the form of anxiety and anxiety.

The study, led by Karolinska Institutet, means that you will receive a number of questionnaires that chart how much trouble you have with heart palpitations; both how often you have your inconvenience and the extent to which they involve mental discomfort for you and if a person-centered clarification of underlying heart rhythm in heart palpitations can lead to improved quality of life.

Access to a Coala for 2 months

As a participant in the study, you get access to a Coala Heart Monitor, which allows you to register your ECG daily (morning and evening and when symptoms occur) during 2 months using your own smartphone.

Recruiting 1,000 women

The number of participants in the RedHeart Study is limited to 1,000 women with an address in Sweden. When the study is complete, the application closes. Participation is free and no compensation is paid for participation in the study. The usual patient injury compensation applies to this study.

For more info on the study in Swedish, see here.

Background and purpose

Heart palpitations are common, and women experience more frequent and more pronounced symptoms than men. Palpitations are usually a benign symptom, but can nevertheless lead to symptoms such as anxiety, anxiety and panic disorder. The mental symptoms are usually found in an anxiety for underlying severe heart disease or that the heart should stop and cause sudden death.

The study intends to investigate to what extent Coala Heart Monitor can map the rhythm disturbance of sporadic behavioral symptoms of cardiac palpitations in the home environment of women. Furthermore, the study aims to investigate whether a person-centered clarification of underlying heart rhythms can lead to a reduced degree of cardiac palpitations as well as mental symptoms and improved quality of life.

Responsible for the study

  • Med Dr Per Insulander, Chief Physician, Karolinska University Hospital and Karolinska Institute
  • Professor Mats Jensen-Urstad, Chief Physician, Karolinska University Hospital
  • Professor Karin Schenck-Gustafsson, Center for Genital Medicine, Karolinska Institutet
  • Research Nurse Carina Carnlöf, Karolinska University Hospital

Coala Life introduces novel, next generation smart algorithms for the heart


See Swedish version here.

Stockholm, 18 dec, 2017 - Coala Life has developed a portfolio of user-centered digital solutions for monitoring the heart. Coala has now released a set of enhanced, smart algorithms enabling remote visualization as well as unique interpretation tools to help objectively detect noise related disturbances in the heart, such as murmurs.

Visualization is made possible in the Coala Care portal. Through the portal, caregivers can easily connect to users of the Coala Heart Monitor and Coala Heart Monitor Pro remotely, based on the users consent. The Coala Care 1.3 release includes new, smart digital interpretation tools, a unique digital Phonocardiogram and the ability to follow individual trends.

- We’ve taken another industry leap by introducing novel digital algorithms and tools for cardiac assessment based on strong user engagement. Besides real-time, cloud based analysis, our unique new tools allow for correlation and visualization of the heart’s synchronous mechanical and electrical characteristics. This helps clinicians to remotely detect early signs of heart disease based on the power of the individual; comments Philip Siberg, CEO of Coala Life AB.


The Coala Heart Monitor and Coala Heart Monitor Pro are powered by smart algorithms that enable detection of 10 different arrhythmias through high quality chest- and thumb-ECG, with synchronous heart sound recording. The Coala Heart Monitor is marketed OTC directly to consumers with CE-approval for use in home environments. The Coala Pro is marketed to healthcare providers to enable smarter and more efficient digital cardiac investigations based on patient engagement. Data is made available in the cloud through the Coala Care Portal, and is free of charge for healthcare providers to join and remotely connect to users.

For more info:

Philip Siberg, Chief Executive Officer, +46 70 7906734,

Titti Lundgren, Chief Marketing Officer, +46 708 3533 28,

Coala wins honorary "Best Pitch" award at Sweden Demo Day 2017

Swe demo day brown paper.jpg

Sweden Demo Day is the largest event of its kind in Sweden where entrepreneurs and investors meet. This year's event attracted over 1,600 people, of which 600 entrepreneurs. Organizers, sponsors and actors are listed as the Swedish Agency for Growth, the Swedish Foundation for Internet Establishment, Vinnova, Business Sweden, EQT Ventures and the Industrial Fund.

Coala Life was pre-qualified as one of 100 finalists to pitch the case for the prominent jury and big audience - and first prize as "Best Pitch 2017" went to Coala Life!

For more information about Sweden Demo Day, see

See swedish version here.

Coala Life receives major grant from the Swedish Governmental Agency for Innovation Systems to further develop Artificial Intelligence to enable early prediction of heart disease

Vinnova Coala Life.png

See Swedish version here.

Coala Life has, in partnership with Region Gävleborg och Cardiolund Research AB, received a governmental grant of 1.2 million SEK to further develop an AI-based system for cardiac disease prediction.

The project goal is to develop, integrate, train and clinically validate an AI-based system for outcome prediction. The AI system will be integrated into the CE-approved Coala Heart Monitor and scientifically verified on patients within the Region of Gävleborg.

Through AI, individualized and prevention-oriented heart screening is made possible in the home environment. If a likelihood of a certain diagnosis becomes high then the user can be warned early. Early detection of abnormalities provides opportunities for early prevention and ultimately improved public health, eg by preventing stroke cases with the treatment of anticoagulants.

To read full article in Swedish, see here.

Swedish startup company and global life science company Bayer initiate partnership

Coala Life Bayer samarbete hjärtmonitor.jpg

See Swedish version here.

STOCKHOLM, 26 OCT, 2017. The Swedish medical technology company Coala Life AB and the life science company Bayer AB initiate partnership in the field of cardiac care. The partnership aims to find the many patients with undiagnosed heart disease, treat and help avoid myocardial infarction and stroke. By introducing new digital cardiac monitoring in the care chain, patients with undiscovered cardiovascular disease can be treated early.

Coala Life is a Swedish fast-growing startup company in the field of digital health. The company was founded based on more than 10 years of R&D, and has recently launched unique digital solutions for monitoring and diagnosing the heart. The company has developed the Coala Heart Monitor, a hardware and cloud based solution that enables effective arrhythmia investigations, early detection of heart disease and an easier way to follow the heart over time. Efficient monitoring enables for earlier treatment and improved outcomes. Coala Life has received numerous awards for its service and internationally praised for its potential to both improve heart disease and save patients’ lives.

-  This is a unique collaboration where the combination of innovative medical technology and world-leading pharmaceuticals will help to digitize, streamline and relieve heart care. Together with Bayer, one of the world's largest pharmaceutical companies in cardiovascular care, we now create common prerequisites for finding and treating cardiac patients earlier, thus helping to win the battle against the world's leading health disease, said Philip Siberg, CEO of Coala Life.

Today, the lack of proper diagnosis is estimated to be around 25 percent among cardiovascular diseases. Only in Sweden, some doctors believe that there are 300,000 people who have not yet been diagnosed. There are evident opportunities to save lives as cardiovascular disease is the most common cause of death in the world.

For more information contact:

Titti Lundgren, CMO Coala Life, +46 70-835 33 28,

For questions to Bayer:

Joseffa Moritz, Communication Manager Bayer Sweden, 073-301 75 52,

About Coala Life

Coala Life is a Swedish medical technology company focused on cardiac diagnostics and mobile health. The company has developed a portfolio of patented products and services for digital remote monitoring and screening of the heart. All products are developed and manufactured in Sweden. 

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. . In 2016, Bayer had approximately 115,000 employees and a turnover of 46.8 billion euros. Capital expenses amounted to EUR 2.6 billion and R&D investments to EUR 4.7 billion. and

Coala Life wins the Rising Star Award 2017


Coala Life winner of the Rising Star Award 2017

Stockholm, Aug 28, 2017 - At the Swedish-American Life Science Summit 2017 (SALSS) in Stockholm, Coala Life was honored as the winner of first Rising Star Award 2017. The award recognizes a Swedish Life Science company that has the capacity to revolutionize and influence a global market.

"We are incredibly proud and honored by this prestigious award. The impressive, world acclaimed jury of The Rising Star Award proves that Swedish research and development is truly world-class and has the ability to impact the globe." said Philip Siberg, CEO of Coala Life.

SALSS is an exclusive conference that attracts some of the Life Science industry's most significant researchers, business leaders, entrepreneurs and investors. The goal is to collaborate and create strategic relations between academia, industry and financiers, thus developing the global Life Science industry. The theme of this year´s conference was Cancer Moonshot, HealthTech Transformation and Impact Investing.

The Rising Star Award includes mentoring by the distinguished jury and introductions to international contacts. The prize was presented by jury member Susanne Najafi at a ceremony held at Nasdaq in Stockholm. The jury concluded:

We are proud to award Coala Life the SALSS 2017 Rising Star Award, for being a novel company with commercial potential, great impact and early approval.

 Coala is well advanced with their product and business model. It is highly scalable and the product is based on consumer insights. The main product is in the analysis of the data, not in the physical product that could be replaced by other market leaders. It also makes a significant impact as it helps detect one of the biggest causes of death today.

 The company is pursuing the hot space of mobile patient centered digital device technologies, applied for better monitoring of heart functions. This can improve future medical practice by integrating patient information continuously rather than episodically. They have already advanced a product to the local Swedish market and is now expanding into new customer segments.”

The international jury consisted of:

Dr. Robert LangerProfessor, MIT.   
Dr. Mikael DolstenPresident Worldwide R&D, Pfizer 
Dr. Carl-Henrik Heldin, Professor and Chairman, The Nobel Foundation
Dr. Eugen SteinerPartner, HealthCap 
Ms. Susanne NajafiEntrepreneur & Investor, Founding Partner Backing Minds 

For more information

Titti Lundgren, CMO, +46 70 8353328,

Philip Siberg, CEO, + 46 70 7906734,

Ylva Nicolae Santesson, Senior Project Manager SALSS, 070 2792524,


About Coala Life AB

Coala Life is a Swedish digital health venture company focused on cardiac diagnostics and mobile health. The company has developed a portfolio of patented medical products and services for digital remote monitoring and screening of the heart. Coala's solutions enable analysis, remote monitoring, more effective cardiac assessments and integrated care services, all in real time. Coala has analyzed over 1.2 million heartbeats.


The Swedish-American Life Science Summit (SALSS) is a by-invitation-only conference bringing together some of the most renowned Life Science executives, scientists, entrepreneurs and investors. The aim is to build strategic and collaborative relationships between academia, industry and fundings, thus enhancing Life Science business. SALSS was founded in 2005 as an initiative to increase the level of cross-border business between one of the largest market in the world, the United States, and one of the most important Life Science industry centers in Europe, Sweden.

The SALSS Rising Star Jury 2017

Professor David H. Koch Institute, MIT

Dr. Robert Langer, David H. Koch Institute Professor, MIT. Professor Langer has written over 1,250 articles and he also holds nearly 1,050 patents worldwide. Dr. Langer´s patents have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies. Furthermore, Dr. Langer is the most cited engineer in history. He served as a member of the United States Food and Drug Administration´s SCIENCE Board, the FDA´s highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to2002. Dr. Langer has received over 220 major awards and is one of seven individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011). He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world´s largest technology prize, the 2012 Priestley Medal, the highest award of the American Chemical Society, the 2013 Wolf Prize in Chemistry, the 2014 Breakthrough Prize in Life Sciences and the 2014 Kyoto Prize. He is the also the only engineer ever to receive the Gairdner Foundation International Award.

Chairman, The Nobel Foundation | Director, Ludwig Cancer Research

Dr. Heldin was the Branch Director of the Ludwig Institute for Cancer Research in Uppsala 1986-2017, and since 1992 he is also Professor in Molecular Cell Biology at Uppsala University where he obtained his PhD in Medical and Physiological Chemistry in 1980. Dr. Heldin is a member of the European Molecular Biology Organization, the Royal Swedish Academy of Sciences and Academia Europea. Dr. Heldin was a Vice President of the European Research Council until 2014, and is also an Associate Editor for Molecular Biology of the Cell, Genes to Cells and Growth Factors. He has received several scientific awards, including Prix Antoine Lacassagne in 1989, K. Fernströms Large Medical Prize in 1993 and the Pezcoller-American Association for Cancer Research Award 2002. Dr. Heldin is also serving on the board or scientific advisory board of several Life Science companies.

President, Worldwide Research & Development, Pfizer

Dr. Dolsten is focused on advancing the company’s scientific leadership in small molecule medicines, biotherapeutics, and vaccines. He is a member of the Pfizer Executive Leadership Team and the company´s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities. He leads the Worldwide Research and Development (WRD) organization at Pfizer, which is responsible for research at the company, including development of all compounds through proof of concept, and provides safety, regulatory and clinical operation support to the entire R&D pipeline. The WRD group contains all Pfizer research units, including Oncology, Cardiovascular & Metabolic Disease, Neuroscience, Inflammation & Immunology, Vaccines, Rare Disease, as well as the Centers for Therapeutic Innovation (CTI) and the biotech unit, Rinat. Dr. Dolsten, also, has worldwide responsibility for Pfizer´s groups in safety, regulatory and external R&D innovation, in addition to science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Prior to joining Pfizer in 2009, Dr. Dolsten was President of Wyeth Research, where he led scientists across the U.S., Europe, and Asia. Dr. Dolsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden, where he was appointed Adjunct Professor in Tumor Immunology. He is a fellow of the New York Academy of Medicine. Dr. Dolsten serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals. Dr. Dolsten was recently elected as Foreign Member of The Royal Swedish Academy of Engineering Sciences. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals.

Entrepreneur, Investor & Founding Partner, Backing Minds

Ms. Najafi is an entrepreneur and investor. She is the founder of Venture Capital firm Backing Minds that invests beyond the homogeneous networks, in underinvested entrepreneurs that is normally missed by traditional VCs. Ms. Najafi grew up outside of Stockholm by Iranian parents and set an early goal in life to start a company that had 100 million in sales before the age of 30. She reached the goal with Eleven, one of Nordics largest e-commercial companies within beauty care where she was the founder and CEO. She has also founded 3 other companies within e-commerce and tech. She has a background as Brand Manager from Procter&Gamble and as a MSc-graduate in Business and Economics and CEMS from Stockholm School of Economics. Ms. Najafi is on the board of listed Stockmann and Lindex and has received several awards e.g. Young Leader of the Year 2015, Most Influential Founder under 40 by Dagens Industri and Entrepreneur Mama of the year 2016.

Venture Partner | HealthCap

Dr. Steiner has 30 years executive management experience as CEO or executive chairman in development stage life-science companies. As a venture partner of HealthCap, a leading European healthcare venture capital fund, he has since 1997 successfully organized and managed several start-up teams in companies which have been financed in part by HealthCap and has led financing efforts in these, which have succeeded in raising in total of over 500 million SEK from Swedish, European and US investors, enabling those companies to execute their strategies and to grow. Dr. Steiner is on the board of several public and private life-science companies as well as of the Stockholm School of Entrepreneurship. Until 1987, Dr. Steiner practiced medicine and was active in pharmacological research at the Karolinska Hospital, Sweden. Dr. Steiner received his medical degree from Karolinska Institute, and earned a Ph.D. in Clinical Pharmacology.